These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31156429)

  • 1. Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.
    Miroshnichenko S; Patutina O
    Front Pharmacol; 2019; 10():488. PubMed ID: 31156429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments.
    To KKW; Fong W; Tong CWS; Wu M; Yan W; Cho WCS
    Expert Opin Drug Discov; 2020 Jan; 15(1):63-83. PubMed ID: 31739699
    [No Abstract]   [Full Text] [Related]  

  • 3. miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells.
    Patutina OA; Bichenkova EV; Miroshnichenko SK; Mironova NL; Trivoluzzi LT; Burusco KK; Bryce RA; Vlassov VV; Zenkova MA
    Biomaterials; 2017 Apr; 122():163-178. PubMed ID: 28126663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA as an Important Target for Anticancer Drug Development.
    Fu Z; Wang L; Li S; Chen F; Au-Yeung KK; Shi C
    Front Pharmacol; 2021; 12():736323. PubMed ID: 34512363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
    Bayraktar E; Bayraktar R; Oztatlici H; Lopez-Berestein G; Amero P; Rodriguez-Aguayo C
    Noncoding RNA; 2023 Apr; 9(2):. PubMed ID: 37104009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient and specific inhibition of plant microRNA function by anti-microRNA oligonucleotides (AMOs) in vitro and in vivo.
    He L; Xie M; Huang J; Zhang T; Shi S; Tang T
    Plant Cell Rep; 2016 Apr; 35(4):933-45. PubMed ID: 26792284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of microRNAs in cancer.
    Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
    Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents.
    Baumann V; Winkler J
    Future Med Chem; 2014; 6(17):1967-84. PubMed ID: 25495987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual miRNases for Triple Incision of miRNA Target: Design Concept and Catalytic Performance.
    Patutina O; Chiglintseva D; Bichenkova E; Gaponova S; Mironova N; Vlassov V; Zenkova M
    Molecules; 2020 May; 25(10):. PubMed ID: 32466298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.
    Rolfo C; Fanale D; Hong DS; Tsimberidou AM; Piha-Paul SA; Pauwels P; Van Meerbeeck JP; Caruso S; Bazan V; Cicero G; Russo A; Giovannetti E
    Curr Pharm Biotechnol; 2014; 15(5):475-85. PubMed ID: 24846062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy.
    Eckburg A; Dein J; Berei J; Schrank Z; Puri N
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated miRNAs and their therapeutic potential.
    Inoue J; Inazawa J
    J Hum Genet; 2021 Sep; 66(9):937-945. PubMed ID: 34088973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review on oncogenic miRNAs in breast cancer.
    Maryam M; Naemi M; Hasani SS
    J Genet; 2021; 100():. PubMed ID: 33764337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single Shot vs. Cocktail: A Comparison of Mono- and Combinative Application of miRNA-Targeted Mesyl Oligonucleotides for Efficient Antitumor Therapy.
    Gaponova S; Patutina O; Sen'kova A; Burakova E; Savin I; Markov A; Shmendel E; Maslov M; Stetsenko D; Vlassov V; Zenkova M
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs as targets for antisense-based therapeutics.
    Stenvang J; Kauppinen S
    Expert Opin Biol Ther; 2008 Jan; 8(1):59-81. PubMed ID: 18081537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic Knockdown of miR-21 by Artificial Ribonuclease: Biological Performance in Tumor Model.
    Patutina OA; Miroshnichenko SK; Mironova NL; Sen'kova AV; Bichenkova EV; Clarke DJ; Vlassov VV; Zenkova MA
    Front Pharmacol; 2019; 10():879. PubMed ID: 31456683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiRNA as potential biomarkers and therapeutic targets for gastric cancer.
    Shin VY; Chu KM
    World J Gastroenterol; 2014 Aug; 20(30):10432-9. PubMed ID: 25132759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
    Wen D; Danquah M; Chaudhary AK; Mahato RI
    J Control Release; 2015 Dec; 219():237-247. PubMed ID: 26256260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.